COLL Q1 2023 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$145M+72.9% YoY

Gross Profit

$77M53.5% margin

Operating Income

$25M17.0% margin

Net Income

-$17M-12.0% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

+11.7%

Cash Flow

Operating Cash Flow

$28M

Free Cash Flow

$27M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$1.0B

Stockholders' Equity

$180M

Cash & Equivalents

$269M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$145M	$84M	+72.9%
Gross Profit	$77M	$48M	+59.6%
Operating Income	$25M	-$10M	+345.9%
Net Income	-$17M	-$13M	-33.3%

Revenue Segments

Xtampza ER

$48M33%

Belbuca

$44M31%

Nucynta IR

$28M19%

Nucynta ER

$21M15%

Symproic

$4M3%